tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Hutchmed downgraded to Hold from Buy at HSBC
The FlyHutchmed downgraded to Hold from Buy at HSBC
6d ago
HCM
HUTCHMED Successfully Passes All Resolutions at 2025 AGM
PremiumCompany Announcements
HUTCHMED Successfully Passes All Resolutions at 2025 AGM
7d ago
HUTCHMED to Showcase New Data at AACR 2025, Enhancing Oncology Portfolio
PremiumCompany Announcements
HUTCHMED to Showcase New Data at AACR 2025, Enhancing Oncology Portfolio
26d ago
HUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric Cancer
PremiumCompany Announcements
HUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric Cancer
28d ago
HUTCHMED Releases 2024 Annual Report and Announces Hybrid AGM
PremiumCompany Announcements
HUTCHMED Releases 2024 Annual Report and Announces Hybrid AGM
1M ago
HUTCHMED Announces Approval of Key Resolution at Extraordinary General Meeting
PremiumCompany AnnouncementsHUTCHMED Announces Approval of Key Resolution at Extraordinary General Meeting
2M ago
Hutchmed says NDA for Tazverik granted conditional approval in China
Premium
The Fly
Hutchmed says NDA for Tazverik granted conditional approval in China
2M ago
HCM
HUTCHMED Secures NMPA Approval for TAZVERIK® in China
Premium
Company Announcements
HUTCHMED Secures NMPA Approval for TAZVERIK® in China
2M ago
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
PremiumRatings
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
2M ago
HCM
HUTCHMED Announces Board Changes Following Director Retirements
PremiumCompany Announcements
HUTCHMED Announces Board Changes Following Director Retirements
2M ago
HUTCHMED’s Savolitinib Shows Promising Results in Lung Cancer Trials
PremiumCompany Announcements
HUTCHMED’s Savolitinib Shows Promising Results in Lung Cancer Trials
2M ago
HUTCHMED Files Annual Report with SEC, Affirming Market Position
PremiumCompany Announcements
HUTCHMED Files Annual Report with SEC, Affirming Market Position
2M ago
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
PremiumThe FlyHutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
2M ago
HCM
Hutchmed reports FY24 EPS 22c vs. 59c last year
Premium
The Fly
Hutchmed reports FY24 EPS 22c vs. 59c last year
2M ago
HCM
HUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments
Premium
Company Announcements
HUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments
2M ago
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
PremiumThe Fly
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
2M ago
HCM
HUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma
PremiumCompany Announcements
HUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma
2M ago
HUTCHMED Announces Vesting of LTIP Awards
PremiumCompany Announcements
HUTCHMED Announces Vesting of LTIP Awards
2M ago
HUTCHMED Adopts 2025 Long Term Incentive Plan to Drive Growth
PremiumCompany Announcements
HUTCHMED Adopts 2025 Long Term Incentive Plan to Drive Growth
2M ago
HUTCHMED Announces EGM for Strategic Disposal Approval
PremiumCompany AnnouncementsHUTCHMED Announces EGM for Strategic Disposal Approval
2M ago
Hutchmed completes enrollment of fanregratinib trial
Premium
The Fly
Hutchmed completes enrollment of fanregratinib trial
2M ago
HCM
HUTCHMED Appoints Alvin Wong as Independent Non-executive Director
Premium
Company Announcements
HUTCHMED Appoints Alvin Wong as Independent Non-executive Director
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >